Intranasal TXA for Anterior Epistaxis in the Emergency Department

Paused · Phase 2 · Has a placebo group

Conditions studied: Epistaxis

In brief

The objective of this study is to evaluate the efficacy of and patient satisfaction with the use of intranasal tranexamic acid (TXA) for anterior nosebleeds in the emergency department (ED).

Key facts

Study ID

NCT04054687

Run by

Mercy Health Ohio

People needed

86

Starts

2019-11-07

Expected to finish

2021-05-01

Last updated by the study team

2020-09-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Patients 18 years and older with anterior epistaxis

You may not qualify if…

• Patients with inability to give consent
• Patients without a working telephone number
• Patients lacking the mental capacity to make their own decisions
• Patients with posterior epistaxis
• Epistaxis following major trauma
• Patients with known bleeding disorder like hemophilia and thrombocytopenia
• Prisoners
• Patients hemodynamically unstable
• Pregnant patients
• Patients with a known allergy to TXA
• Patients with a visibly bleeding vessel
• Those recently post-op nasal/sinus surgery (within ten days) will also be excluded

Where it is running

• St Elizabeth Boardman Hospital — Boardman, Ohio, United States
• St Elizabeth Youngstown — Youngstown, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.